Is galectin-3 a promoter of ventricular dysfunction?

Lupu, Adrian; Lupu, Silvia; Agoşton-Coldea, Lucia

doi:10.2478/rrlm-2018-0001

Cited by 3 publications

(2 citation statements)

References 67 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The detailed information about the role of galectin-3 in mediation of inflammation by different pathways is presented in an extensive review by Lupu et al In this review the clinical utility of the detection of this biomarker is provided. (9) Another important tool involved in progression of chronic HF, oxidative stress and inflammation, was investigated by Iliesiu et al The objective of this study was to evaluate the association between seric uric acid, oxidative stress and inflammation markers in patients with moderate-severe HF reduced left ventricular ejection fraction. It was shown that elevated level of uric acid is correlated with disease severity and in the absence of renal failure may mirror increased xanthine-oxidase activity associated with chronic inflammatory response.…”

Section: Biomarkers Beyond Clinical Utilitymentioning

confidence: 99%

Biomarkers in heart failure: from the bedside back to biology

Rustamova

Dobreanu

2018

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

Section: Biomarkers Beyond Clinical Utilitymentioning

confidence: 99%

Biomarkers in heart failure: from the bedside back to biology

Rustamova

Dobreanu

2018

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

“…According to Kubanek M. et al [17] galectin-3 plays an important role in the initial stages of heart failure formation and is an important predictor of left ventricular hypertrophy. One of the certain limitations in estimating the prognostic value of galectin-3 is the dependence on sexual and age-related differences, as well as on the size of renal glomerular filtration [19].…”

Section: Introductionmentioning

confidence: 99%

Galectin-3 - a modern biomarker for the diagnosis of left ventricular hypertrophy and chronic heart failure and control of treatment of patients with hypertension

Ruzhanska

Sivak

Полищук

et al. 2018

Biomed. and Biosoc. Anthrop.

View full text Add to dashboard Cite

The development of new methods for the prevention and treatment of chronic heart failure and its control is an urgent medical and social problem. In this regard, using of new biological markers of the disease may be useful for early diagnosis of the disease, predict a clinical course, monitor the effects of pharmacotherapy (personalized medicine) and play an important role in stratifying the patient's risk. In 2013, according to the recommendation of the American Heart Association, a galectin-3 was introduced into the pool of such biomarkers for prevention and treatment of chronic heart failure. Objective: to improve prediction of the course and effectiveness of the therapy for hypertension and chronic heart failure as the hypertension complication in men 40-60 years old by applying the level of galectin-3 as a biomarker. There were observed the men 40-60 years old with hypertension and chronic heart failure for the concentration of galectin-3. Also, there were observed subjects without cardiovascular pathology (n=79), the men with hypertonic disease with myocardial hypertension (n=62) and the men with chronic heart failure II-III functional class of NYHA (n=50) for the indicators of central and systemic hemodynamics. The level of galectin-3 was determined by immunoassay analysis on the equipment "Stat Fact 300". Structural and functional parameters of myocardium were assessed by an ultrasound method using the equipment "RADMIR ULTIMARA". Data statistical analysis was performed on a personal computer using standard statistical package "Statistica 10.0". All data is presented in the form of average (M) and standard deviation (± σ). It has been established that the concentration of galectin-3 significantly decreases against the background of treatment. The level of galectin-3 in the patients with the II stage of hypertonic disease with good treatment effect was close to normal values compared to those with moderate treatment effect. In terms of patients with hypertension III stage, the level of galectin-3 also decreased, indicating the possibility of therapy monitoring using this biomarker. The mathematical model of the galectin-3 influencing factors also has been determined in patients with hypertension. The boundary level of the galectin-3 has been calculated, it is counted 46.51 pg/ml. It might be assumed a moderate effect of the treatment of hypertensive patients and chronic heart failure in males.

show abstract

Proposal of a prediction model for prognosis of patients with acute myocardial infarction after percutaneous coronary intervention based on galectin-3 and soluble growth stimulating expressed gene 2 levels

Zhang

Song

et al. 2022

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

Background: To study the correlations of serum galectin-3 (Gal-3) and soluble growth stimulating expressed gene 2 (sST2) levels with prognosis of patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Methods: A total of 112 patients diagnosed from August 2015 to October 2017 were selected. They were followed up for 3 years. Based on major adverse cardiovascular events (MACEs) during follow-up, they were divided into MACE and non-MACE groups. Multivariate logistic regression analysis was performed to explore the independent risk factors for MACEs. A nomogram model was established using the factors and validated. The optimal cut-off values of Gal-3 and sST2 levels were determined by receiver operating characteristic curves. Kaplan-Meier method was used for survival analysis. Results: MACEs occurred in 78 patients during follow-up. Patients in the MACE group were more often hypertensive, had higher total cholesterol, uric acid, sST2 and Gal-3, and lower left ventricular ejection fraction (LVEF) (P<0.05). CK-MB, sST2, Gal-3 and LVEF were the independent risk factors for MACEs (P<0.05). The nomogram model established with these factors had high accuracy for predicting overall survival, and its concordance index (C-index) was 0.768 (95% confidence interval: 0.692-0.865). The prognosis of the patients with Gal-3 ≥12.57 μg/ mL and sST2 ≥18.56 ng/mL was poorer 3 years after PCI. Conclusions: The levels of serum Gal-3 and sST2 are the independent risk factors for MACEs in AMI patients following PCI, with high prognostic value.

show abstract

Is galectin-3 a promoter of ventricular dysfunction?

Abstract: Heart failure is nowadays a common condition associated with high mortality and increased healthcare-related

Cited by 3 publications

References 67 publications

Biomarkers in heart failure: from the bedside back to biology

Biomarkers in heart failure: from the bedside back to biology

Galectin-3 - a modern biomarker for the diagnosis of left ventricular hypertrophy and chronic heart failure and control of treatment of patients with hypertension

Proposal of a prediction model for prognosis of patients with acute myocardial infarction after percutaneous coronary intervention based on galectin-3 and soluble growth stimulating expressed gene 2 levels

Contact Info

Product

Resources

About